Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostics Molecular Tests

Thyroid

ThyGenX ThyraMIR logos

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient

Pancreas

PancraGen logo

PancraGEN™ is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient.

I am a physician
I am a patient

In the Pipeline: Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Barrett’s Esophagus

Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

BarreGEN Logo

Pancreatobiliary Cancer

Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings

Announcements

Interpace Diagnostics Announces Coverage of Thyroid Test by Oxford Health Plans

PARSIPPANY, N.J., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient [...]

Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent Accomplishments

Aug 10, 2017 (GLOBE NEWSWIRE via COMTEX) -- Net Revenue Grew 7% Over the Prior Year Comparable Quarter and 11% Over the First Quarter of 2017  Raised Over $22 Million in Capital in Past 6 [...]

Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Thursday August 10, 2017

PARSIPPANY, N.J., Aug 09, 2017 (GLOBE NEWSWIRE via COMTEX) -- Interpace Diagnostics Group, Inc. IDXG, -1.60% ("Interpace" or "the Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient [...]

View All

Updates

Interpace Diagnostics: Developing Advanced Molecular Diagnostic Tests for Cancer

Interpace Diagnostics: Developing Advanced Molecular Diagnostic Tests for Cancer […]

Managing Patients With Pancreatic Cystic Lesions

David Loren, MD, Thomas Jefferson University, shares data on the molecular test, PancraGen, which helps identify false negative cases that could be missed by first-line tests like imaging, cytology and fluid chemistry. […]